Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases.

autoimmune bullous dermatosis bullous pemphigoid covid-19 vaccine immunology imputability pemhigus vulgaris superficial pemphigus

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Mar 2022
Historique:
accepted: 13 03 2022
entrez: 15 4 2022
pubmed: 16 4 2022
medline: 16 4 2022
Statut: epublish

Résumé

Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We hypothesized that vaccination against coronavirus disease 2019 (COVID-19) could trigger an immunological response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. Clinical and histopathological examinations confirmed the diagnosis of bullous pemphigoid (BP) in three patients and pemphigus in the other two. According to the French method of imputability, the pharmacovigilance investigation showed an I5B4 causality assessment score for the vaccines, interpreted as highly probable, for all the patients. The diagnosis of vaccine-induced autoimmune bullous dermatosis was highly suspected. One patient's condition improved by dermocorticoids alone, while the other four required oral corticosteroid therapy at 0.5 mg/kg/day, which led to a favorable outcome.

Identifiants

pubmed: 35425676
doi: 10.7759/cureus.23127
pmc: PMC9004698
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e23127

Informations de copyright

Copyright © 2022, Hali et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e645-e647
pubmed: 34169578
Indian J Dermatol Venereol Leprol. 2020 Jan-Feb;86(1):66-68
pubmed: 31823906
Biomolecules. 2020 Oct 10;10(10):
pubmed: 33050407
Int J Rheum Dis. 2022 Jan;25(1):83-85
pubmed: 34766739
Therapie. 2019 Dec;74(6):557-567
pubmed: 31623850
Cell Mol Immunol. 2018 Jun;15(6):586-594
pubmed: 29503439
Med Clin (Barc). 2021 Nov 26;157(10):e333-e334
pubmed: 34119340
Indian Pediatr. 2016 May 8;53(5):425-6
pubmed: 27254056
Front Med (Lausanne). 2021 Dec 20;8:807711
pubmed: 34988105
Clin Dermatol. 2021 May-Jun;39(3):359-368
pubmed: 34517993
J Comp Pathol. 2007 Jul;137 Suppl 1:S57-61
pubmed: 17548092
J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1133-40
pubmed: 24404939
Autoimmunity. 2006 Nov;39(7):541-7
pubmed: 17101497

Auteurs

Fouzia Hali (F)

Dermatology, Ibn Rochd University Hospital Center, Casablanca, MAR.

Lamiae Araqi (L)

Dermatology, Ibn Rochd University Hospital Center, Casablanca, MAR.

Farida Marnissi (F)

Anatomical Pathology, Ibn Rochd University Hospital Center, Casablanca, MAR.

Ahlam Meftah (A)

Pharmacology, Ibn Rochd University Hospital Center, Casablanca, MAR.

Soumiya Chiheb (S)

Dermatology, Ibn Rochd University Hospital Center, Casablanca, MAR.

Classifications MeSH